News Conference News CX Symposium 2025 Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices L.A. McKeown April 23, 2025
News Conference News LINC 2023 PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD L.A. McKeown June 21, 2023
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News TCT 2020 IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs L.A. McKeown October 18, 2020
News Conference News LINC 2020 DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets L.A. McKeown January 30, 2020
News Conference News LINC 2020 COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose L.A. McKeown January 28, 2020
News Conference News TCT 2019 ‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures L.A. McKeown September 28, 2019
News Conference News EuroPCR 2019 EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal L.A. McKeown May 23, 2019
News Conference News VIVA 2016 Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option L.A. McKeown October 12, 2016
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016
News Conference News ISET 2016 Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired Michael O'Riordan February 10, 2016
News Conference News VEITH 2015 DCBs for Femoropoliteal Disease: What’s Now and What’s Next? Yael L. Maxwell November 19, 2015
News Conference News EuroPCR 2015 Studies Provide Encouraging Results for DCB in Long SFA Lesions Caitlin E. Cox May 22, 2015